Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2022; 10(4): 1286-1290
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1286
Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report
Juan Zhang, Xin Wang, Jing-Jing Tian, Rong Zhu, Rui-Xue Duo, Yi-Chen Huang, Hai-Li Shen
Juan Zhang, Xin Wang, Jing-Jing Tian, Rong Zhu, Rui-Xue Duo, Hai-Li Shen, Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou 730030, Gansu Province, China
Yi-Chen Huang, Second Clinical Medical College, Lanzhou University, Lanzhou 730030, Gansu Province, China
Author contributions: Shen HL and Zhang J designed the research and wrote the paper; Zhang J, Wang X, Tian JJ, Zhu R, Duo RX, and Huang YC collected all the data related to the case report; Shen HL supervised the report; all authors have read and approved the final manuscript.
Supported by the Lanzhou Science and Technology Plan Project, No. 2018-3-48; Lanzhou Talent Innovation and Entrepreneurship Project, No. 2019-RC-35; and 2019 Special Fund for Doctoral Training of Lanzhou University Second Hospital, No. YJS-BD-15.
Informed consent statement: Written informed consent was obtained from the patient.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Li Shen, Chief Doctor, Department of Rheumatology, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou 730030, Gansu Province, China. shenhl_523@163.com
Received: July 29, 2021
Peer-review started: July 29, 2021
First decision: October 25, 2021
Revised: November 3, 2021
Accepted: December 23, 2021
Article in press: December 23, 2021
Published online: February 6, 2022
Core Tip

Core Tip: Primary Sjögren's syndrome (pSS) concomitant with autoimmune hemolytic anemia (AIHA) but without eye and mouth dryness is exceedingly rare. Iguratimod (IGU) has been widely used in the treatment of pSS. However, there are few reports about the application of IGU in pSS concomitant with AIHA. Here, we present the case of a patient with pSS concomitant with AIHA who was successfully treated with IGU. IGU was effective for and well tolerated by our patient with pSS concomitant with AIHA, and may be a promising therapy for treatment of this disease.